Julie Tay appointed as independent director

1 May 2023

NZX/ASX Code: EBO

Julie Tay appointed as independent director

EBOS Group Limited (EBOS) is pleased to announce the appointment of Julie Tay as an independent
director, effective 15 May 2023.

Ms Tay joins EBOS with over 30 years’ experience in international executive and non-executive roles
across consumer healthcare, medical devices and digital healthcare.

Ms Tay is currently a director of Sonova Holdings, a global hearing care solutions company,
headquartered in Switzerland and listed on the Swiss stock exchange.

During her executive career, Ms Tay was most recently Senior Vice President and Managing Director,
Asia Pacific for Align Technology, which is a global medical device company focused on the
orthodontic and dental markets. In this role she launched Align Technology in Asia and, over nine
years, established the company’s primary product, Invisalign, as a leading brand across 14 markets.
During this time, Ms Tay was also a member of the global Executive Management Committee for
Align Technology.

Prior to this time, Ms Tay was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and
also previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson.

Ms Tay holds a Bachelor of Psychology and Political Science from the National University of
Singapore and an MBA from Curtin University of Technology in Perth. Ms Tay has also completed the
International Directors Program at INSEAD.

EBOS Chair Liz Coutts said “Julie’s extensive experience in Asia within the healthcare sector will be
invaluable to EBOS as we explore expansion opportunities in the region. We look forward to
welcoming her to the Board.”

The Board has determined that Ms Tay will be an independent director (as defined in the NZX Listing
Rules). Ms Tay resides in Singapore.

This appointment is consistent with EBOS’ Board succession planning previously announced. EBOS
has appointed three new directors within the last two years with a diverse mix of skills. The Board
now comprises eight directors, all of whom are independent.

For further information please contact:
Martin Krauskopf
Executive General Manager, Strategy and Mergers & Acquisitions
+61 3 9918 5555

Authorised for lodgement with NZX and ASX by Janelle Cain, General Counsel, EBOS Group
Limited.

About EBOS Group

EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified
Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical
products. It is also a leading Australasian animal care brand owner, product marketer and
distributor.